Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Debt: 2019-2024

Historic Non-Current Debt for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $738.9 million.

  • BridgeBio Pharma's Non-Current Debt rose 69.73% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 69.73%. This contributed to the annual value of $738.9 million for FY2024, which is 65.50% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Non-Current Debt is $738.9 million, which was up 65.50% from $446.4 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Debt peaked at $738.9 million during FY2024, and registered a low of $92.4 million during FY2020.
  • For the 3-year period, BridgeBio Pharma's Non-Current Debt averaged around $538.8 million, with its median value being $446.4 million (2023).
  • Data for BridgeBio Pharma's Non-Current Debt shows a peak YoY surged of 366.08% (in 2021) over the last 5 years.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Debt (Yearly) stood at $92.4 million in 2020, then skyrocketed by 366.08% to $430.8 million in 2021, then increased by 0.06% to $431.0 million in 2022, then increased by 3.59% to $446.4 million in 2023, then skyrocketed by 65.50% to $738.9 million in 2024.